Mental state: significant response or improvement in negative symptoms (PANSS negative subscale, high = worse) ‐ short term (12 weeks) · adults with schizophrenia
It is very uncertain whether noradrenaline reuptake inhibitors changes mental state: significant response or improvement in negative… compared with placebo (very low certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · adults with schizophrenia
1 finding from 1 review
Clinical global response: significant response or improvement in global status (CGI‐S, high = worse) ‐ short term (4 weeks) · adults with schizophrenia
It is very uncertain whether noradrenaline reuptake inhibitors changes clinical global response: significant response or improvement in… compared with placebo (very low certainty).
1 finding from 1 review
Cognitive functioning: significant response or improvement in cognitive functioning · adults with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive function: average endpoint score** · adults with schizophrenia
1 finding from 1 review
QoL · adults with schizophrenia
1 finding from 1 review
Nausea · adults with schizophrenia
Noradrenaline reuptake inhibitors showed no clear difference in adverse effects: Nausea ‐ short term (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors may leads to higher self‐reported pain relief of 50% or greater compared with placebo (low certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors may leads to higher patient Global Impression to be much or very much improved (PGIC) compared with placebo (low certainty).
1 finding from 1 review
Fatigue · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors showed no clear difference in self‐reported fatigue (20‐100 scale) Higher scores indicate higher… compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors showed no clear difference in self‐reported sleep problems (0‐100 scale) Higher scores indicate… compared with placebo (low certainty).
1 finding from 1 review
Self‐reported health‐related quality of life (0‐100 scale) Higher scores indicate higher burden of disease (lower quality of life) · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors showed no clear difference in self‐reported health‐related quality of life (0‐100 scale) Higher… compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors may leads to higher tolerability (withdrawal due to adverse events) compared with placebo (low certainty).
1 finding from 1 review
Safety Any serious adverse event · patients with fibromyalgia
It is very uncertain whether serotonin noradrenaline reuptake inhibitors changes safety (serious adverse events) compared with placebo (very low certainty).
1 finding from 1 review